

IPO Expected Timetable#

Stock Code	Stock Name	Application lists close	Allotment Date	Listing Date
02162	KEYMED BIO-B	2021/06/30	2021/07/07	2021/07/08
09868	XPENG-W	2021/06/30	2021/07/06	2021/07/07

#IPO listed above are those with fundraising amount more than HK\$500M. For more IPO information, please visit www.cfs.com.hk or contact our account executives or customer service officers

Subscription Details via CASH Securities

KEYMED BIO-B(02162)

Offer Period	2021/06/25-2021/06/30
Closing Time for Margin Application	2021/06/29 2:00pm
Subscription Fee	HKD 100
Days For Margin Financing	7 days
Indicative Interest Rate	2.68% (0.25% deductible [^]) [^] Eligible new and existing customers who use the electronic direct debit authorization (eDDA) transfer service before the termination of the IPO subscription can enjoy a 0.25% loan interest reduction.

*The deadline for margin subscription share will be changed at any time, which is available on a first-come-first-served basis.

XPENG-W(09868)

Offer Period	2021/06/25-2021/06/30
Closing Time for Margin Application	N/A
Subscription Fee	N/A
Days For Margin Financing	N/A
Indicative Interest Rate	N/A

*The deadline for margin subscription share will be changed at any time, which is available on a first-come-first-served basis.

Keymed Biosciences Inc. (2162.HK)

Share Offer Highlights

Total Number of Offer Shares:	58,264,500 Shares (subject to the Overallotment Option)
- Number of Public Offer Shares:	5,827,000 Shares (subject to reallocation)
- Number of Placing Shares:	52,437,500 Shares, consisting of new Shares only (subject to reallocation and the Over-allotment Option)
Number of Shares per Lot:	500 Shares
Offer Price:	HKD 50.50-53.30 per Share
2020 Historical P/E ratio:	-
Sponsor:	Morgan Stanley, CICC, HUATAI International

Company Overview

Founded in 2016, the Company is a biotechnology company focused on the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas. It has one Core Product, CM310, an antagonist antibody against interleukin- 4 receptor -subunit (IL-4R), intended to treat various allergic diseases, such as moderate-to-severe atopic dermatitis (AD), moderate-to-severe eosinophilic asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP), and potentially chronic obstructive pulmonary disease (COPD). It has been able to continuously discover and develop new drug candidates in these therapeutic areas and in addition to our Core Product, its pipeline includes eight drug candidates at various stages of development, of which five are clinical-stage drug candidates that each are among the first three domestically-developed for its target or in its class to have obtained IND approval in China and/or the U.S., and three are in investigational new drug (IND)-enabling stage.

For the year ended December 31, 2019 and 2020, the Company's net losses were RMB 167.51 mn, and RMB 818.58 mn respectively.



XPeng Inc. (9868.HK)

Share Offer Highlights

Total Number of Offer Shares:	85,000,000 Offer Shares (subject to the Over-allotment Option)
- Number of Public Offer Shares:	4,250,000 Offer Shares (subject to reallocation)
- Number of Placing Shares:	80,750,000 Offer Shares (subject to reallocation and the Over-allotment Option)
Number of Shares per Lot:	100 Shares
Offer Price:	HKD 180.00 per Share
2020 Historical P/E ratio:	-
Sponsor:	J.P.Morgan , BofA SECURITIES

Company Overview

Within only six years since its inception in 2015, the Company has become one of the leading Smart EV companies in China, with leading software, data and hardware technology at its core and bringing innovation in autonomous driving, smart connectivity and core vehicle systems. In contrast to incumbent automotive original equipment manufacturers, or OEMs, and some pure-play EV startups, who generally rely on software solutions from third-party suppliers, its speed of innovation and unique capability to tailor its vehicle software to evolving needs of Chinese consumers and China-specific road conditions are its core competitive advantages. As of the Latest Practicable Date, it is the only automotive company based in China that develops full stack autonomous driving software encompassing localization and high definition map fusion, perception algorithm and sensor fusion, behavior planning, motion planning and control in house and has deployed such software on mass-produced vehicles according to IHS Markit.

For the year ended December 31, 2018, 2019 and 2020, the Company's net profits were RMB 2,254.86 mn, RMB 4,642.75 mn, and RMB 4,889.72 mn respectively.

Source

IPO Prospectus

Contact Us

Headquarters:	22/F, Manhattan Place, 23 Wang Tai Road, Kowloon Bay, Hong Kong	(852) 2287 8788
HK Services Centre:	6/F, May May Building, 683-685 Nathan Road, Mongkok, Kowloon	(852) 2748 0110
China Services Centre:	1004A(10/F), AVIC Center, 1018 Huafu Road, Futian District, Shenzhen	(86-755) 2216 5888
	2501, Tower A, China Overseas International Centre, 838 South Huangpi Road, Huangpu District, Shanghai	(86-21) 3227 9888
	Room 3316B, Block A, China Shine Plaza, 9 West Lin He Road, Tian He District, Guangzhou	(020) 8981 7463
	Rm 2511, TBA Tower, 11 Dongguan Avenue, City East District, Dongguan	(86-769) 2223 0026

Declaration:

The above information is provided and distributed by CASH Financial Services Group Limited ("CASH"). The document is for reference only. Neither the information nor opinion expressed shall be construed, expressly or impliedly, as an advice, offer, invitation, advertisement, inducement, recommendation or representation of any kind or form whatsoever. While the information contained herein has been obtained from sources believed to be reliable, CASH or its affiliates do not represent that it is accurate or complete and it should be relied upon. CASH hereby expressly disclaims all liabilities arising out of or incidental to the accuracy and completeness of the contents and information herein contained. The contents and information in this document is subject to change without prior notice to you. Trade in securities covered by this report may be made only in those jurisdictions where the securities are qualified for trading. This document may not in whole or in part be reproduced or furnished to any person other than the addressee without written consent from CASH and CASH shall not be liable to any such third parties for loss arising from any unauthorized distribution. Securities dealing services are provided by Celestial Securities Limited, a corporation licensed to conduct Type 1 (dealing in securities) regulated activity under the Securities and Futures Ordinance.